Surgical Oncology
Deputy Chief Physician, Department of Oncology, Zhongshan Hospital, Xiamen University, China
Selected publications from PubMed
Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial.
Blum Murphy MA, Xiao L, Sewastjanow-Silva M, Wang X, Badgwell BD, Mansfield PF, Ikoma N, Pabon CM, Lee JH, Bhutani MS, Weston B, Coronel E, Smith GL, Holliday EB, Tian J, Barabrah AM, Das P, Minsky BD, Waters RE, Estrella JS, Li JJ, Ajani JA
Cancers (Basel). 2026 Jul 8;18(14) doi: 10.3390/cancers18142198.
Growth Hormone Pathway as a Prognostic and Therapeutic Biomarker in Patients With Unresectable Hepatocellular Carcinoma Treated With Radiation Therapy.
Eid JR, Kaseb S, Xiao L, Sun R, Kannan MK, Hassan M, Rashid A, Cao HST, Amin HM, Koay EJ
Adv Radiat Oncol. 2026 May;11(5):102007 doi: 10.1016/j.adro.2026.102007.
T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2(+) solid and hematologic cancers.
Zhang Y, Xiong W, Qian J, Duan R, Guo Q, Wang Q, Wu W, Zhang C, Li Y, Xian M, Lu Y, Esnaola NF, Chang JC, Xiao L, Zhong L, Yi Q
Nat Commun. 2026 Feb 16;17(1) doi: 10.1038/s41467-026-69621-8.
Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma.
Eid JR, Yalciner M, Xiao L, Sun R, Kannan MK, Hassan M, Rashid A, Chamseddine S, Tran Cao HS, Amin HM, Kaseb AO
J Hepatocell Carcinoma. 2025;12:2709-2722 doi: 10.2147/JHC.S560112.
PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation.
Zheng P, Hu Z, Shen Y, Gu L, Ouyang Y, Duan Y, Ji G, Dong B, Lin Y, Wen T, Tian Q, Hou Y, Zhou Q, Sun X, Chen X, Wang KL, Luo S, Wu S, Sun Y, Li M, Xiao L, Wu Q, Meng Y, Liu G, Wang Z, Bai X, Duan S, Ding Y, Bi Y, Wang Y, Li G, Liu X, Lu Z, Wu X, Tang Z, Xu D
Nat Chem Biol. 2025 Sep;21(9):1420-1432 doi: 10.1038/s41589-025-01887-3.
Help your network discover Dr. Li Xiao's clinical expertise.
